Cowen reissued their buy rating on shares of Natera (NASDAQ:NTRA) in a research note released on Thursday. They currently have a $12.00 target price on the medical research company’s stock.

A number of other analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Natera from a sell rating to a hold rating in a research note on Friday, September 22nd. Morgan Stanley reiterated an overweight rating and set a $16.00 price objective (up previously from $13.00) on shares of Natera in a research note on Friday, October 6th. Canaccord Genuity reiterated a buy rating and set a $15.00 price objective on shares of Natera in a research note on Tuesday, November 14th. Robert W. Baird reiterated a buy rating on shares of Natera in a research note on Tuesday, October 24th. Finally, BidaskClub upgraded shares of Natera from a sell rating to a hold rating in a research note on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $14.50.

Natera (NTRA) traded down $0.24 on Thursday, hitting $9.61. 92,600 shares of the stock were exchanged, compared to its average volume of 191,111. Natera has a 12 month low of $7.35 and a 12 month high of $14.76. The company has a debt-to-equity ratio of 2.43, a quick ratio of 1.75 and a current ratio of 1.85.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $56.66 million for the quarter, compared to analysts’ expectations of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.50) EPS. equities research analysts predict that Natera will post -2.15 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Wells Fargo & Company MN increased its stake in shares of Natera by 2.8% in the second quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock worth $195,000 after buying an additional 491 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Natera by 1.3% in the second quarter. Principal Financial Group Inc. now owns 112,687 shares of the medical research company’s stock worth $1,224,000 after buying an additional 1,409 shares during the last quarter. Voya Investment Management LLC increased its stake in shares of Natera by 17.8% in the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock worth $159,000 after buying an additional 2,212 shares during the last quarter. Strs Ohio increased its stake in shares of Natera by 5.9% in the second quarter. Strs Ohio now owns 60,800 shares of the medical research company’s stock worth $660,000 after buying an additional 3,400 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Natera by 8.2% during the second quarter. California State Teachers Retirement System now owns 55,589 shares of the medical research company’s stock valued at $604,000 after purchasing an additional 4,200 shares during the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Natera (NTRA) Given “Buy” Rating at Cowen” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/natera-ntra-given-buy-rating-at-cowen/1778394.html.

Natera Company Profile

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with Analyst Ratings Network's FREE daily email newsletter.